Please login to the form below

Not currently logged in
Email:
Password:

Ogeda

This page shows the latest Ogeda news and features for those working in and with pharma, biotech and healthcare.

Bayer moves vilaprisan into phase III trials for uterine fibroids

Bayer moves vilaprisan into phase III trials for uterine fibroids

have acquired Ogeda and its phase IIa candidate Fezolinetant.

Latest news

  • Astellas agrees €800m deal to buy Belgian biotech Ogeda Astellas agrees €800m deal to buy Belgian biotech Ogeda

    Astellas agrees 800m deal to buy Belgian biotech Ogeda. Will pay another 300m if fezolinetant meets clinical and regulatory targets. ... The parties expect the deal to close this quarter, after which Ogeda will become a wholly-owned subsidiary of Astellas

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    An example of a big pharma buying a company with a new technology/ product is Astellas which acquired the venture capital owned Belgian company Ogeda for up to $872m. ... Ogeda is developing drugs targeting G-protein coupled receptors. The lead product

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics